Report

Handelen med medisinske varer og Covid-19

Published: 4 May 2020
Summary:

The Covid-19 pandemy has exposed vulnerability for pharmaceuticals and medical goods. Does globalisation create more or less vulnerability?
- The majority of countries import all their drugs and only eighteen countries are net exporters.
- Exports are dominated by Western Europa, with China and India some way down the list.
- Globalisation has spread the risk for medical goods by an increased number of suppliers and less export concentration. A main driver is increased export from small European countries.
- At a more detailed level of goods, the picture is more mixed, with growing concentration in some cases.
- Export restrictions contribute to market collapse and higher prices, that particularly hit poor countries that import all their needs.
- For Norway, European integration is important for medical contingency planning.